Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

CNDAC-induced DNA double strand breaks cause aberrant mitosis prior to cell death.

Liu X, Jiang Y, Takata KI, Nowak B, Liu C, Wood RD, Hittelman WN, Plunkett W.

Mol Cancer Ther. 2019 Sep 9. pii: molcanther.1380.2018. doi: 10.1158/1535-7163.MCT-18-1380. [Epub ahead of print]

PMID:
31501277
2.

Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.

Cheung LH, Zhao Y, Alvarez-Cienfuegos A, Mohamedali KA, Cao YJ, Hittelman WN, Rosenblum MG.

J Exp Clin Cancer Res. 2019 Jul 30;38(1):332. doi: 10.1186/s13046-019-1333-6.

3.

COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.

Lindemann A, Patel AA, Silver NL, Tang L, Liu Z, Wang L, Tanaka N, Rao X, Takahashi H, Maduka NK, Zhao M, Chen TC, Liu W, Gao M, Wang J, Frank SJ, Hittelman WN, Mills GB, Myers JN, Osman AA.

Clin Cancer Res. 2019 Sep 15;25(18):5650-5662. doi: 10.1158/1078-0432.CCR-19-0096. Epub 2019 Jul 15.

PMID:
31308060
4.

Regulating nociceptive transmission by VGluT2-expressing spinal dorsal horn neurons.

Wang L, Chen SR, Ma H, Chen H, Hittelman WN, Pan HL.

J Neurochem. 2018 Nov;147(4):526-540. doi: 10.1111/jnc.14588. Epub 2018 Oct 31.

5.

CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition.

Gadhikar MA, Zhang J, Shen L, Rao X, Wang J, Zhao M, Kalu NN, Johnson FM, Byers LA, Heymach J, Hittelman WN, Udayakumar D, Pandita RK, Pandita TK, Pickering CR, Redwood AB, Piwnica-Worms H, Schlacher K, Frederick MJ, Myers JN.

Cancer Res. 2018 Feb 1;78(3):781-797. doi: 10.1158/0008-5472.CAN-17-2802. Epub 2017 Dec 11.

6.

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation.

Delgado M, Kothari A, Hittelman WN, Chambers TC.

J Vis Exp. 2017 Nov 10;(129). doi: 10.3791/56418.

7.

Differentiation of Human Induced Pluripotent or Embryonic Stem Cells Decreases the DNA Damage Repair by Homologous Recombination.

Mujoo K, Pandita RK, Tiwari A, Charaka V, Chakraborty S, Singh DK, Hambarde S, Hittelman WN, Horikoshi N, Hunt CR, Khanna KK, Kots AY, Butler EB, Murad F, Pandita TK.

Stem Cell Reports. 2017 Nov 14;9(5):1660-1674. doi: 10.1016/j.stemcr.2017.10.002. Epub 2017 Nov 2.

8.

Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation.

Tanaka N, Patel AA, Tang L, Silver NL, Lindemann A, Takahashi H, Jaksik R, Rao X, Kalu NN, Chen TC, Wang J, Frederick MJ, Johnson F, Gleber-Netto FO, Fu S, Kimmel M, Wang J, Hittelman WN, Pickering CR, Myers JN, Osman AA.

Clin Cancer Res. 2017 Nov 1;23(21):6541-6554. doi: 10.1158/1078-0432.CCR-17-0947. Epub 2017 Aug 8.

9.

Cell Cycle-Dependent Mechanisms Underlie Vincristine-Induced Death of Primary Acute Lymphoblastic Leukemia Cells.

Kothari A, Hittelman WN, Chambers TC.

Cancer Res. 2016 Jun 15;76(12):3553-61. doi: 10.1158/0008-5472.CAN-15-2104. Epub 2016 May 6.

10.

Chloride Homeostasis Critically Regulates Synaptic NMDA Receptor Activity in Neuropathic Pain.

Li L, Chen SR, Chen H, Wen L, Hittelman WN, Xie JD, Pan HL.

Cell Rep. 2016 May 17;15(7):1376-1383. doi: 10.1016/j.celrep.2016.04.039. Epub 2016 May 5.

11.

Pannexin-1 Up-regulation in the Dorsal Root Ganglion Contributes to Neuropathic Pain Development.

Zhang Y, Laumet G, Chen SR, Hittelman WN, Pan HL.

J Biol Chem. 2015 Jun 5;290(23):14647-55. doi: 10.1074/jbc.M115.650218. Epub 2015 Apr 29.

12.

Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.

Zhou H, Mohamedali KA, Gonzalez-Angulo AM, Cao Y, Migliorini M, Cheung LH, LoBello J, Lei X, Qi Y, Hittelman WN, Winkles JA, Tran NL, Rosenblum MG.

Mol Cancer Ther. 2014 Nov;13(11):2688-705. doi: 10.1158/1535-7163.MCT-14-0346. Epub 2014 Sep 19.

13.

MOF phosphorylation by ATM regulates 53BP1-mediated double-strand break repair pathway choice.

Gupta A, Hunt CR, Hegde ML, Chakraborty S, Chakraborty S, Udayakumar D, Horikoshi N, Singh M, Ramnarain DB, Hittelman WN, Namjoshi S, Asaithamby A, Hazra TK, Ludwig T, Pandita RK, Tyler JK, Pandita TK.

Cell Rep. 2014 Jul 10;8(1):177-89. doi: 10.1016/j.celrep.2014.05.044. Epub 2014 Jun 19. Erratum in: Cell Rep. 2014 Jul 10;8(1):319.

14.

Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.

Wen Y, Zand B, Ozpolat B, Szczepanski MJ, Lu C, Yuca E, Carroll AR, Alpay N, Bartholomeusz C, Tekedereli I, Kang Y, Rupaimoole R, Pecot CV, Dalton HJ, Hernandez A, Lokshin A, Lutgendorf SK, Liu J, Hittelman WN, Chen WY, Lopez-Berestein G, Szajnik M, Ueno NT, Coleman RL, Sood AK.

Cell Rep. 2014 Apr 24;7(2):488-500. doi: 10.1016/j.celrep.2014.03.009. Epub 2014 Apr 3.

15.

Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair.

Morales JC, Richard P, Rommel A, Fattah FJ, Motea EA, Patidar PL, Xiao L, Leskov K, Wu SY, Hittelman WN, Chiang CM, Manley JL, Boothman DA.

Nucleic Acids Res. 2014 Apr;42(8):4996-5006. doi: 10.1093/nar/gku160. Epub 2014 Mar 3.

16.

The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth.

Mohamedali KA, Cao Y, Cheung LH, Hittelman WN, Rosenblum MG.

Mol Cancer Ther. 2013 Oct;12(10):2055-66. doi: 10.1158/1535-7163.MCT-13-0165. Epub 2013 Jul 15.

17.

Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.

Zhou H, Hittelman WN, Yagita H, Cheung LH, Martin SS, Winkles JA, Rosenblum MG.

Cancer Res. 2013 Jul 15;73(14):4439-50. doi: 10.1158/0008-5472.CAN-13-0187. Epub 2013 May 30.

18.

Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu.

Cao Y, Mohamedali KA, Marks JW, Cheung LH, Hittelman WN, Rosenblum MG.

Mol Cancer Ther. 2013 Jun;12(6):979-91. doi: 10.1158/1535-7163.MCT-13-0002. Epub 2013 Mar 14.

19.

T-cell-specific deletion of Mof blocks their differentiation and results in genomic instability in mice.

Gupta A, Hunt CR, Pandita RK, Pae J, Komal K, Singh M, Shay JW, Kumar R, Ariizumi K, Horikoshi N, Hittelman WN, Guha C, Ludwig T, Pandita TK.

Mutagenesis. 2013 May;28(3):263-70. doi: 10.1093/mutage/ges080. Epub 2013 Feb 5.

20.

Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.

Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG.

Oncogene. 2014 Jan 23;33(4):429-39. doi: 10.1038/onc.2012.612. Epub 2013 Feb 4.

21.

The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.

Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum MG.

J Invest Dermatol. 2013 Apr;133(4):1052-62. doi: 10.1038/jid.2012.402. Epub 2012 Nov 29.

22.

Programming in situ immunofluorescence intensities through interchangeable reactions of dynamic DNA complexes.

Zimak J, Schweller RM, Duose DY, Hittelman WN, Diehl MR.

Chembiochem. 2012 Dec 21;13(18):2722-8. doi: 10.1002/cbic.201200525. Epub 2012 Nov 20.

23.

Multiplexed in situ immunofluorescence using dynamic DNA complexes.

Schweller RM, Zimak J, Duose DY, Qutub AA, Hittelman WN, Diehl MR.

Angew Chem Int Ed Engl. 2012 Sep 10;51(37):9292-6. doi: 10.1002/anie.201204304. Epub 2012 Aug 15. No abstract available.

24.

The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.

Lyu MA, Pham LV, Sung B, Tamayo AT, Ahn KS, Hittelman WN, Cheung LH, Marks JW, Cho MJ, Ford RJ, Aggarwal BB, Rosenblum MG.

Biochem Pharmacol. 2012 Aug 15;84(4):451-8. doi: 10.1016/j.bcp.2012.05.019. Epub 2012 Jun 9.

PMID:
22687624
25.

Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system.

Naguib M, Xu JJ, Diaz P, Brown DL, Cogdell D, Bie B, Hu J, Craig S, Hittelman WN.

Anesth Analg. 2012 May;114(5):1104-20. doi: 10.1213/ANE.0b013e31824b0191. Epub 2012 Mar 5.

26.

Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique mitochondrial toxin.

Lyu MA, Cheung LH, Hittelman WN, Liu Y, Marks JW, Cho MJ, Rosenblum MG.

Cancer Lett. 2012 Sep 28;322(2):159-68. doi: 10.1016/j.canlet.2012.02.029. Epub 2012 Mar 1.

PMID:
22388102
27.

Configuring robust DNA strand displacement reactions for in situ molecular analyses.

Duose DY, Schweller RM, Zimak J, Rogers AR, Hittelman WN, Diehl MR.

Nucleic Acids Res. 2012 Apr;40(7):3289-98. doi: 10.1093/nar/gkr1209. Epub 2011 Dec 11.

28.

Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.

Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG.

Mol Cancer Ther. 2012 Jan;11(1):143-53. doi: 10.1158/1535-7163.MCT-11-0519. Epub 2011 Nov 16.

29.

Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2.

Mohamedali KA, Ran S, Gomez-Manzano C, Ramdas L, Xu J, Kim S, Cheung LH, Hittelman WN, Zhang W, Waltenberger J, Thorpe PE, Rosenblum MG.

BMC Cancer. 2011 Aug 17;11:358. doi: 10.1186/1471-2407-11-358.

30.

Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.

Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, Winkles JA.

Mol Cancer Ther. 2011 Jul;10(7):1276-88. doi: 10.1158/1535-7163.MCT-11-0161. Epub 2011 May 17.

31.

RING finger and WD repeat domain 3 (RFWD3) associates with replication protein A (RPA) and facilitates RPA-mediated DNA damage response.

Liu S, Chu J, Yucer N, Leng M, Wang SY, Chen BP, Hittelman WN, Wang Y.

J Biol Chem. 2011 Jun 24;286(25):22314-22. doi: 10.1074/jbc.M111.222802. Epub 2011 May 9.

32.

Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model.

Lee J, Ryu SH, Kang SM, Chung WC, Gold KA, Kim ES, Hittelman WN, Ki Hong W, Koo JS.

Cancer Prev Res (Phila). 2011 Aug;4(8):1306-15. doi: 10.1158/1940-6207.CAPR-10-0364. Epub 2011 Apr 19.

33.

Multiplexed and reiterative fluorescence labeling via DNA circuitry.

Duose DY, Schweller RM, Hittelman WN, Diehl MR.

Bioconjug Chem. 2010 Dec 15;21(12):2327-31. doi: 10.1021/bc100348q. Epub 2010 Nov 16.

34.

Are cancer stem cells radioresistant?

Hittelman WN, Liao Y, Wang L, Milas L.

Future Oncol. 2010 Oct;6(10):1563-76. doi: 10.2217/fon.10.121. Review.

35.

Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.

Zhou H, Liu Y, Cheung LH, Kim S, Zhang W, Mohamedali KA, Anand P, Hittelman WN, Aggarwal BB, Rosenblum MG.

Neoplasia. 2010 Oct;12(10):766-77.

36.

Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype.

Robertson FM, Ogasawara MA, Ye Z, Chu K, Pickei R, Debeb BG, Woodward WA, Hittelman WN, Cristofanilli M, Barsky SH.

J Biomol Screen. 2010 Aug;15(7):820-9. doi: 10.1177/1087057110376541. Epub 2010 Jul 16.

PMID:
20639504
37.

Sensing of blood pressure increase by transient receptor potential vanilloid 1 receptors on baroreceptors.

Sun H, Li DP, Chen SR, Hittelman WN, Pan HL.

J Pharmacol Exp Ther. 2009 Dec;331(3):851-9. doi: 10.1124/jpet.109.160473. Epub 2009 Sep 2.

38.

Enhanced response to C225 of A431 tumor xenografts growing in irradiated tumor bed.

Riesterer O, Mason KA, Raju U, Yang Q, Wang L, Hittelman WN, Ang KK, Milas L.

Radiother Oncol. 2009 Sep;92(3):383-7. doi: 10.1016/j.radonc.2009.07.009. Epub 2009 Aug 18.

PMID:
19695723
39.

Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience.

Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M.

Oncology. 2009;77(2):75-81. doi: 10.1159/000226772. Epub 2009 Jul 1.

40.

Cancer stem cells and tumor response to therapy: current problems and future prospects.

Milas L, Hittelman WN.

Semin Radiat Oncol. 2009 Apr;19(2):96-105. doi: 10.1016/j.semradonc.2008.11.004. Review.

PMID:
19249647
41.

Cyclin D1 and cancer development in laryngeal premalignancy patients.

Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN Jr, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK.

Cancer Prev Res (Phila). 2009 Jan;2(1):14-21. doi: 10.1158/1940-6207.CAPR-08-0111.

42.

Proliferative changes in the bronchial epithelium of former smokers treated with retinoids.

Hittelman WN, Liu DD, Kurie JM, Lotan R, Lee JS, Khuri F, Ibarguen H, Morice RC, Walsh G, Roth JA, Minna J, Ro JY, Broxson A, Hong WK, Lee JJ.

J Natl Cancer Inst. 2007 Nov 7;99(21):1603-12. Epub 2007 Oct 30.

43.

Workshop on imaging science development for cancer prevention and preemption.

Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee.

Cancer Biomark. 2007;3(1):1-33.

PMID:
17655039
44.

Molecular mechanisms in Barrett's metaplasia and its progression.

Izzo JG, Luthra R, Wu TT, Correa AM, Luthra M, Anandasabapathy S, Chao KS, Hung MC, Aggarwal B, Hittelman WN, Ajani JA.

Semin Oncol. 2007 Apr;34(2 Suppl 1):S2-6.

PMID:
17449347
45.

Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma.

Izzo JG, Wu TT, Wu X, Ensor J, Luthra R, Pan J, Correa A, Swisher SG, Chao CK, Hittelman WN, Ajani JA.

J Clin Oncol. 2007 Feb 20;25(6):698-707.

PMID:
17308274
46.

The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.

Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, Rosenblum MG.

Mol Cancer Ther. 2007 Feb;6(2):460-70. Epub 2007 Jan 31.

47.

Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma.

Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA.

Mol Cancer Ther. 2006 Nov;5(11):2844-50.

48.

Deficiency of cell cycle checkpoints and DNA repair system predispose individuals to esophageal cancer.

Shao L, Hittelman WN, Lin J, Yang H, Ajani JA, Wu X.

Mutat Res. 2006 Dec 1;602(1-2):143-50. Epub 2006 Oct 2.

PMID:
17011594
49.

Rad17 phosphorylation is required for claspin recruitment and Chk1 activation in response to replication stress.

Wang X, Zou L, Lu T, Bao S, Hurov KE, Hittelman WN, Elledge SJ, Li L.

Mol Cell. 2006 Aug 4;23(3):331-41.

50.

Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.

Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA.

J Clin Oncol. 2006 Aug 10;24(23):3789-98. Epub 2006 Jun 19.

PMID:
16785472

Supplemental Content

Loading ...
Support Center